Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments

Camille Tessier, Richard Leblanc, Jean Roy, Sabrina Trudel, Julie Cote, Marc Lalancette, Jean-Samuel Boudreault, Emilie Lemieux-Blanchard, Rayan Kaedbey, Michel Pavic

Blood (2023) 142 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2023-173362

Published: 2023

Journal Articles

Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study

Andree-Anne Pelland, Xavier Savard, Frederic Barabe, Vincent Laroche, Michaël Munger, Genevieve Gallagher, Nicolas Marcoux, Guy Cantin, Maxime Chénard-Poirier, Robert Delage, Marc Lalancette, Christopher Lemieux

Blood (2022) 140 (Supplement 1): 3304–3305.

https://doi.org/10.1182/blood-2022-170223

Published: 2022

Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay

Blood (2019) 134 (Supplement_1): 1871.

https://doi.org/10.1182/blood-2019-122637

Published: 2019

Journal Articles

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J. White, MD, Andrew R Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Andrea Kew, MDFRCP(C), Marc Lalancette, MD FRCP, Martha L Louzada, MD, Arleigh McCurdy, MD BSc, Gail T. McDonald, Tony Reiman, MD, Laura Rodriguez, Lois E. Shepherd, Engin Gul, BSc, Bingshu E. Chen, Annette E Hay

Blood (2018) 132 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2018-99-117824

Published: 2018

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Philippe Moreau, MDPhD, Albert Oriol, MD, Jonathan L. Kaufman, MD, Heather Sutherland, MD, Marc Lalancette, MD FRCP, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, MD PhD, Miles Prince, MD FRACP, FRCPA, Tara Cochrane, Lisa O'Rourke, MSN, RN, Kaida Wu, Jordan M. Schecter, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1883.

https://doi.org/10.1182/blood.V130.Suppl_1.1883.1883

Published: 2017

Journal Articles

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Blood (2016) 128 (22): 3330.

https://doi.org/10.1182/blood.V128.22.3330.3330

Published: 2016

Journal Articles

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Philippe Moreau, Jonathan L. Kaufman, MD, Heather J. Sutherland, MD PhD, Marc Lalancette, MDFRCP-C, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, Miles Prince, MD, Tara Cochrane, Nushmia Z Khokhar, Mary Guckert, Xiang Qin, Albert Oriol

Blood (2016) 128 (22): 489.

https://doi.org/10.1182/blood.V128.22.489.489

Published: 2016

Journal Articles

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Blood (2016) 128 (22): 977.

https://doi.org/10.1182/blood.V128.22.977.977

Published: 2016

Journal Articles

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Dennis Dong Hwan Kim, MD PhD, Mary Lynn Savoie, MD, Isabelle Bence-Bruckler, MD FRCPC, Lothar B. Huebsch, MD, Marc Lalancette, MDFRCP-C, Christopher M. Hillis, MD FRCPC, Irwin Walker, MBBS, Donna L. Forrest, MD, Jeff H. Lipton, MD PhD

Blood (2016) 128 (22): 1907.

https://doi.org/10.1182/blood.V128.22.1907.1907

Published: 2016

Journal Articles

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT

Blood (2005) 106 (9): 2969–2976.

https://doi.org/10.1182/blood-2004-09-3544

Published: 2005

Journal Articles

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT

Blood (2005) 105 (11): 4532–4539.

https://doi.org/10.1182/blood-2004-06-2387

Published: 2005

NARROW

Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments

Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only